What Is Tirzepatide? The Dual GIP/GLP-1 Agonist
Tirzepatide
22.5% Weight Loss
Participants on tirzepatide 15 mg in SURMOUNT-1 lost an average of 22.5% of body weight over 72 weeks, the largest reduction seen in any GLP-1 class trial.
Jastreboff et al., NEJM, 2022
Jastreboff et al., NEJM, 2022
View as imageTirzepatide is a synthetic peptide that activates two incretin hormone receptors simultaneously: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). This dual mechanism, sometimes called "twincretin" action, produces greater weight loss and glucose reduction than GLP-1-only drugs like semaglutide. In the SURMOUNT-1 trial, participants on the highest dose lost an average of 22.5% of body weight over 72 weeks.[1] This article explains what tirzepatide is, how it works at the receptor level, and what the clinical trial evidence shows.
Key Takeaways
- Tirzepatide is a 39-amino-acid peptide that activates both GIP and GLP-1 receptors, with higher affinity for GIP receptors than GLP-1 receptors (Nauck et al., 2022)
- In SURMOUNT-1, tirzepatide 15 mg produced 22.5% mean weight loss at 72 weeks, compared to 3.1% for placebo in people without diabetes (Jastreboff et al., 2022)
- Head-to-head against semaglutide 1 mg in SURPASS-2, tirzepatide 15 mg reduced HbA1c by 2.46% vs 1.86% for semaglutide (Frias et al., 2021)
- Tirzepatide improved insulin sensitivity beyond what weight loss alone would explain, suggesting GIP receptor activation has independent metabolic effects (Thomas et al., 2021)
- Sold as Mounjaro (for type 2 diabetes, approved 2022) and Zepbound (for obesity, approved 2023), both are the same molecule at the same doses
- GIP receptor activation increases fat oxidation and may improve lipid handling in adipose tissue, complementing GLP-1's appetite-suppressing effects
The Two Receptors: GLP-1 and GIP
To understand tirzepatide, you need to understand the two hormones it mimics.
GLP-1 (glucagon-like peptide-1) is secreted by L-cells in the distal small intestine after eating. It stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and acts on brain regions that control appetite and food reward. GLP-1 is the target of semaglutide, liraglutide, and other established GLP-1 receptor agonists.
GIP (glucose-dependent insulinotropic polypeptide) is secreted by K-cells in the proximal small intestine. It is the body's most potent incretin, responsible for roughly 60-70% of the meal-stimulated insulin response in healthy individuals. GIP also acts on adipose tissue, bone, and the central nervous system. For decades, GIP was considered a less promising drug target because its insulinotropic effect appeared blunted in people with type 2 diabetes. Tirzepatide challenged that assumption.
The two hormones are complementary. GLP-1 dominates appetite suppression and gastric slowing. GIP dominates insulin potentiation and may improve fat metabolism. Together, they produce effects that neither achieves alone.
How Tirzepatide Is Built
Tirzepatide is a 39-amino-acid synthetic peptide based on the GIP sequence, engineered with modifications that give it GLP-1 receptor activity as well.[4]
Key structural features:
- GIP backbone: the peptide sequence is derived from native GIP, giving it strong affinity for the GIP receptor (comparable to native GIP)
- GLP-1 cross-reactivity: specific amino acid substitutions enable binding to the GLP-1 receptor, though with approximately 5-fold lower affinity than native GLP-1
- C20 fatty diacid: a lipid chain attached via a linker to Lys20, enabling albumin binding. This extends the half-life to approximately 5 days, allowing once-weekly dosing
- Imbalanced agonism: tirzepatide is not a 50/50 dual agonist. It is biased toward GIP, with GLP-1 activity serving as a secondary mechanism
This imbalanced profile was characterized by Willard et al. (2020), who demonstrated that tirzepatide's signaling at the GLP-1 receptor differs qualitatively from native GLP-1. At the GLP-1 receptor, tirzepatide shows biased agonism, preferentially activating cAMP signaling over beta-arrestin recruitment. This may contribute to reduced GI side effects compared to pure GLP-1 agonists, though the clinical relevance of this signaling bias is still being studied.
What GIP Receptor Activation Adds
The question that defined tirzepatide's development: does adding GIP receptor activation to GLP-1 produce better outcomes than GLP-1 alone?
Thomas et al. (2021) provided early mechanistic evidence.[5] In patients with type 2 diabetes, tirzepatide improved beta-cell function (measured by HOMA2-B) and insulin sensitivity (measured by HOMA2-IR) to a greater extent than dulaglutide (a pure GLP-1 agonist), even after adjusting for weight loss.
The insulin sensitivity improvement is the critical finding. GLP-1 agonists improve insulin sensitivity primarily through weight loss. Tirzepatide appeared to improve it through an additional, weight-independent mechanism. The proposed pathway: GIP receptor activation in adipose tissue enhances lipid storage capacity and reduces ectopic fat deposition in liver and muscle, improving systemic insulin sensitivity.
Additional effects attributed to GIP receptor activation:
- Enhanced fat oxidation: GIP signaling in adipocytes may increase the rate at which stored fat is metabolized
- Improved lipid profiles: tirzepatide reduced triglycerides and increased HDL cholesterol beyond what weight loss alone would predict
- Bone metabolism: GIP receptors are expressed on osteoblasts, and GIP signaling may help preserve bone density during weight loss (this is being studied in ongoing trials)
- Central appetite effects: GIP receptors are present in the hypothalamus, though the specific contribution to appetite regulation versus GLP-1's effects is still being delineated
For a detailed comparison of how the dual mechanism differs from single GLP-1 agonism, see the linked article.
The SURPASS Trials: Diabetes Evidence
The SURPASS program tested tirzepatide in patients with type 2 diabetes across multiple trials. The results established tirzepatide as the most effective incretin-based therapy for glycemic control.[3]
SURPASS-2 was the most revealing trial because it included a head-to-head comparison with semaglutide 1 mg.[2] Over 40 weeks in 1,879 patients with type 2 diabetes:
| Outcome | Tirzepatide 5 mg | Tirzepatide 10 mg | Tirzepatide 15 mg | Semaglutide 1 mg |
|---|---|---|---|---|
| HbA1c reduction | -2.01% | -2.24% | -2.30% | -1.86% |
| Weight loss | -7.6 kg | -9.3 kg | -11.2 kg | -5.7 kg |
| HbA1c <7% achieved | 82% | 86% | 86% | 79% |
All three tirzepatide doses were non-inferior to semaglutide 1 mg for HbA1c reduction, and the 10 mg and 15 mg doses were superior. Weight loss was greater with all tirzepatide doses.
The caveat: semaglutide 1 mg is not the dose used for weight management (that is 2.4 mg). SURPASS-2 compared diabetes doses, not obesity doses. A direct comparison between tirzepatide and semaglutide 2.4 mg for weight loss has not been published. For analysis of how tirzepatide compares to semaglutide in weight loss, see the linked article.
SURMOUNT-1: The Obesity Landmark
The SURMOUNT-1 trial tested tirzepatide specifically for weight management in 2,539 adults without diabetes.[1]
Results at 72 weeks:
| Outcome | Tirzepatide 5 mg | Tirzepatide 10 mg | Tirzepatide 15 mg | Placebo |
|---|---|---|---|---|
| Mean weight loss | -15.0% | -19.5% | -22.5% | -3.1% |
| Lost ≥5% | 85% | 89% | 91% | 35% |
| Lost ≥20% | 32% | 46% | 57% | 3% |
The 22.5% mean weight loss at the 15 mg dose was unprecedented for any single-agent pharmacotherapy. For context, semaglutide 2.4 mg produces approximately 15-17% in comparable trial populations.
More than half of participants on tirzepatide 15 mg achieved at least 20% weight loss, a threshold previously associated primarily with bariatric surgery. This result led to FDA approval of tirzepatide (as Zepbound) for chronic weight management in November 2023.
The SURMOUNT trial program includes additional studies examining long-term outcomes, body composition effects, and outcomes in patients with type 2 diabetes and obesity. For details on how weight loss changes at each dose level, see the linked article.
Mounjaro vs Zepbound: Same Drug, Two Labels
Tirzepatide is sold under two brand names:
- Mounjaro: approved May 2022 for type 2 diabetes. Available in doses of 2.5, 5, 7.5, 10, 12.5, and 15 mg
- Zepbound: approved November 2023 for chronic weight management. Available in the same doses
The molecule is identical. The doses are identical. The pen devices are interchangeable. The difference is regulatory: Mounjaro was approved based on the SURPASS trials (diabetes endpoints), and Zepbound on the SURMOUNT trials (weight endpoints). Insurance coverage, copay programs, and prescribing rules differ between the two labels. For a full breakdown, see Mounjaro vs Zepbound: Understanding Tirzepatide's Two Brand Names.
Side Effect Profile
Tirzepatide's side effects are similar to those of GLP-1-only agonists, dominated by gastrointestinal symptoms:
- Nausea: reported by 12-31% of participants across SURMOUNT-1 (dose-dependent)
- Diarrhea: 12-23%
- Constipation: 6-11%
- Vomiting: 5-13%
Most GI side effects were mild to moderate and occurred primarily during dose escalation. Discontinuation rates due to adverse events were 4.3-7.1% across tirzepatide doses in SURMOUNT-1, compared to 2.6% for placebo.
The biased signaling profile at the GLP-1 receptor (favoring cAMP over beta-arrestin) has been hypothesized to explain why tirzepatide may cause somewhat less nausea per unit of weight loss than semaglutide, though direct head-to-head tolerability data at obesity-indicated doses is limited.
Serious adverse events under investigation include pancreatitis (rare, <0.2% in trials), cholelithiasis (gallstones, more common with rapid weight loss), and the thyroid C-cell tumor signal seen with all GLP-1 class drugs in rodent models. No increase in medullary thyroid carcinoma has been observed in human trials, but the class carries a boxed warning based on the animal data.
Dosing, Administration, and Pharmacokinetics
Tirzepatide is administered as a once-weekly subcutaneous injection using a single-dose pen. The dose escalation schedule follows the same principle as semaglutide: start low, increase gradually to minimize GI side effects.
The standard escalation:
- Weeks 1-4: 2.5 mg (starting dose, not a maintenance dose)
- Week 5+: 5.0 mg (first maintenance dose)
- Increases every 4 weeks: 7.5 mg, then 10 mg, then 12.5 mg, then 15 mg as tolerated
The half-life is approximately 5 days, which is slightly shorter than semaglutide's 7-day half-life. Steady-state concentrations are reached after approximately 4 weeks of weekly dosing. The drug is cleared primarily through proteolytic degradation, not renal or hepatic metabolism, meaning dose adjustments are not required for mild to moderate kidney or liver impairment.
Peak plasma concentrations occur 8-72 hours after injection. The C20 fatty diacid modification enables albumin binding in the bloodstream, which both extends the half-life and creates a circulating reservoir of drug that smooths out the pharmacokinetic curve between weekly doses.
Injection sites include the abdomen, thigh, or upper arm. The pen devices for both Mounjaro and Zepbound are identical and require no reconstitution.
Who Is Eligible
For Mounjaro (type 2 diabetes indication), the prescribing criteria are type 2 diabetes inadequately controlled with diet, exercise, and existing medications. There is no BMI requirement.
For Zepbound (weight management indication), eligibility requires:
- BMI ≥30 (obesity), or
- BMI ≥27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea)
Tirzepatide is not approved for type 1 diabetes, and its use in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 is contraindicated based on the class-wide precaution from rodent thyroid tumor data.
How Tirzepatide Fits in the Incretin Landscape
Tirzepatide represents the second generation of incretin-based therapies. The first generation targeted GLP-1 alone. The emerging third generation includes triple agonists (GLP-1/GIP/glucagon), with retatrutide as the lead candidate.
The trajectory is clear: each generation activates more metabolic pathways and produces greater weight loss. Whether more receptor targets always means better outcomes, or whether diminishing returns and compounding side effects set in, is the open question.
Tirzepatide's position is well-defined: it is the most effective approved anti-obesity medication as of 2026, producing weight loss in the range previously achievable only with surgical intervention. It does this through a mechanism that combines the appetite suppression and gastric slowing of GLP-1 with the metabolic and insulin-sensitizing effects of GIP.
For patients already on semaglutide who have plateaued or are interested in switching, the comparison between the two drugs and the question of what happens when stopping are directly relevant.
The Bottom Line
Tirzepatide is a dual GIP/GLP-1 receptor agonist that produces the largest weight reductions of any approved anti-obesity medication. In SURMOUNT-1, the 15 mg dose achieved 22.5% mean weight loss over 72 weeks. Its dual mechanism combines GLP-1's appetite suppression with GIP's effects on insulin sensitivity and fat metabolism. Head-to-head data from SURPASS-2 showed superiority over semaglutide 1 mg for both glycemic control and weight loss, though a comparison at obesity-indicated doses has not been published.